Inclusion Criteria:

• Subjects aged ≥ 18 years.
• ECOG performance status 0 or 1.
• Subjects must have a documented IDH mutation per immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) testing of tumor tissue.
• Subjects must have histologically or cytologically documented, advanced or metastatic solid malignancy of any type that has recurred or progressed on available standard treatment and for which no curative therapy exists.

Exclusion Criteria:

• Subjects who received an investigational agent < 14 days prior to their first day of study drug administration.
• Subjects who are pregnant or breastfeeding.
• Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever > 38.3°C during screening visits or on their first day of study drug administration.
• Subjects with some current or prior heart conditions.
• Subjects taking medications that are known to prolong the QT interval may not be eligible.
• Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
• Some subjects with some current or prior gastrointestinal or liver diseases.
• Subjects with inadequate organ function as defined by the protocol.